Posted tagged ‘treatment’

Zytiga Becoming a Preferred Treatment for Advanced Prostate Cancer

January 9, 2014

Revenues from Zytiga (abiraterone acetate), Johnson & Johnson’s drug therapy for advanced prostate cancer, have skyrocketed recently, as countries around the world have adopted it and similar therapies as a preferred early treatment option. Zytiga was originally developed by Cougar Biotechnology, where co-founder Lindsay Rosenwald provided support to the drug’s research team. In 2009, Johnson & Johnson bought the company for almost $1 billion. Now, Zytiga is ushering in a new method of treating prostate cancer that is safe and effective and prolongs the lives of patients in the late stages of the disease. Clinical trials currently are testing abiraterone acetate’s effectiveness on other types of cancer as well.

In late 2012, the U.S. Food and Drug Administration approved abiraterone acetate for pre-chemotherapy use in patients with metastatic castration-resistant prostate cancer (mCRPC). The drug stops the body’s production of estrogen and androgens that can cause cancer to grow. More than 65 countries have approved the use of Zytiga, and the drug is becoming a standard treatment for men with mCRPC.

Zerenex Shows Promise for Treating Chronic Kidney Disease

January 3, 2014

Recent data that Keryx Biopharmaceuticals, Inc., released from an extension study of Zerenex show that the drug seems to be safe and easy to tolerate. The two-year study, which should be completed before July 2014, is researching the effects of Zerenex in treating hypertension in patients who are on dialysis and have chronic kidney disease (CKD). Preliminary data support results from a previous long-term phase III study of Zerenex.

The current study enrolled only patients who completed the phase III study, which lasted 58 weeks. Participants will have been exposed to Zerenex for two years, and results so far show that the drug effectively controls serum phosphorus and reduces the need for IV iron while maintaining hemoglobin levels.

The promising nature of the study’s data means that Zerenex could receive Federal Drug Administration approval by mid-2014. The drug has tremendous marketability, as more than 26 million people in the United States suffer from CKD, and more than 8 million of those have moderate to severe cases. Analysts estimate that sales of Zerenex could reach $800 million, although the strong preliminary data from the extension study could boost sales even more.